The Technical Analyst
Syneos Health Inc [SYNH]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Syneos Health Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.02% $42.98
America/New_York / 27 sep 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 457.84 mill |
| EPS: | 0.700 |
| P/E: | 61.40 |
| Earnings Date: | Nov 02, 2023 |
| SharesOutstanding: | 103.72 mill |
| Avg Daily Volume: | 1.324 mill |
| RATING 2023-09-29 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 61.40 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 3.28x |
| Company: PE 61.40 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 42.87 - 43.09 ( +/- 0.25%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-28 | Zulueta Alfonso G | Sell | 3 493 | Class A Common Stock |
| 2023-09-28 | Zulueta Alfonso G | Sell | 4 863 | Class A Common Stock |
| 2023-09-28 | Wilkes David S. | Sell | 4 973 | Class A Common Stock |
| 2023-09-28 | Wilkes David S. | Sell | 4 863 | Class A Common Stock |
| 2023-09-28 | Monaghan Matthew E. | Sell | 19 777 | Class A Common Stock |
| INSIDER POWER |
|---|
| -46.03 |
| Last 97 transactions |
| Buy: 420 799 | Sell: 674 760 |
Forecast:
01:40 - $43.05
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $42.98 (0.02% ) |
| Volume | 6.70 mill |
| Avg. Vol. | 1.324 mill |
| % of Avg. Vol | 506.42 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SYNH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SYNH
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Latest Press Releases
2024-01-04 12:00:00 - Press Release
Crossject Engages Syneos Health For U.s. Commercial Launch Of Zepizure®
Press release crossject engages syneos health for u.s. commercial launch of zepizure ® crossject expanding market access activities in preparation for filing for marketing authorization zepizure®, previously known as zeneo® midazolam, is separately contracted with barda for u.s. advanced regulatory development and specific supply to the strategic national stockpile dijon, france, january 4, 2024, 18:00 cet -- crossject (isin: fr0011716265; uronext: alcj), a specialty pharma company developing needle-free auto-injectors for emergency situations, has engaged syneos health, a leading fully integrated biopharmaceutical solutions organization, to prepare for the commercial launch of crossject's zepizure® innovative rescue therapy for epileptic seizures in the u...
2023-10-05 15:00:00 - Press Release
Elligo Health Research Announces Expansion Of Study Marketplace With Syneos Health
Austin, texas--(business wire)-- #clinicalresearch--elligo health research® today announced it is expanding its study marketplace platform with syneos health.
2023-09-28 10:24:00 - Press Release
Syneos Health Closes Transaction With private Investment Firms
Transaction will drive ongoing transformation and accelerate delivery of tech-enabled, fit-for-purpose solutions to biopharma customers transaction will drive ongoing transformation and accelerate delivery of tech-enabled, fit-for-purpose solutions to biopharma customers
2023-09-26 17:41:00 - Press Release
Civitas Resources Set To Join S&p Midcap 400; Hayward Holdings To Join S&p Smallcap 600
New york , sept. 26, 2023 /prnewswire/ -- s&p smallcap 600 constituent civitas resources inc. (nyse: civi) will replace syneos health inc. (nasd: synh) in the s&p midcap 400, and hayward holdings inc. (nyse: hayw) will replace civitas resources in the s&p smallcap 600 effective prior to the opening of trading on friday, september 29.
2023-09-26 05:45:00 - Press Release
Shareholder Alert: The Gross Law Firm Notifies Shareholders Of Syneos Health, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 25, 2023 - (nasdaq: Synh)
New york , sept. 26, 2023 /prnewswire/ -- the gross law firm issues the following notice to shareholders of syneos health, inc..
Latest News
2023-09-13 09:46:31 - Zacks Investment Research
Syneos Health (SYNH) Declares Strategic Partnership With Oracle
Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.
2023-07-25 11:38:43 - Zacks Investment Research
Earnings Preview: Syneos Health (SYNH) Q2 Earnings Expected to Decline
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2023-06-27 09:03:15 - Zacks Investment Research
Syneos Health (SYNH) Collaborates With uMotif for New Platform
Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.
2023-06-07 14:34:07 - Zacks Investment Research
Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes
Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.
2023-05-11 10:39:44 - Zacks Investment Research
Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement
Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.
2023-05-10 09:55:55 - Zacks Investment Research
Syneos Health (SYNH) Q1 Earnings and Revenues Surpass Estimates
Syneos Health (SYNH) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $1.01 per share a year ago.
2023-05-10 09:29:16 - InvestorPlace
SYNH Stock Alert: The $7 Billion Reason Syneos Health Is Up Today
Syneos Health (NASDAQ: SYNH ) stock is on the rise Wednesday as investors react to news of a $7.1 billion acquisition deal. A group of investors led by Elliott Investment Management intend to take the healthcare company private for a price of $43 per share.
2023-05-10 08:02:00 - Barrons
Syneos Health Stock Rises on $7.1 Billion Sale to Private Group
The sale of Syneos Health comes as the company faces muted spending from drug developers for its clinical-research services.
2023-05-09 16:40:00 - Market Watch
Syneos Health's stock soars 19% on acquisition report
Syneos Health Inc.'s SYNH stock surged 19% in extended trading Tuesday on a Bloomberg report that a consortium of Elliott Investment Management, Patient Square Capital and Veritas Capital is in advanced talks to acquire Syneos, a drug-research services company. A deal could be announced as soon as this week, according to people with knowledge of the talks, the report said.
2023-05-08 09:54:40 - Zacks Investment Research
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.